

Year	Milestones
2011	<ul style="list-style-type: none"> <li>• Revised WHO guidelines for stopping MDA and post-MDA surveillance completed and available</li> <li>• WHO guidelines and criteria for verification of the interruption of LF transmission completed and available</li> <li>• WHO guidelines and training modules for morbidity management completed and available</li> </ul>
2012	<ul style="list-style-type: none"> <li>• LF mapping completed in all countries</li> <li>• MDA started in all countries without co-endemic loiasis</li> <li>• Provisional strategy for LF transmission interruption in loiasis-endemic countries developed and circulated</li> <li>• 25% of endemic countries will have met the criteria for stopping MDA and entered post-intervention surveillance</li> </ul>
2013	<ul style="list-style-type: none"> <li>• Revised strategy for LF transmission interruption implemented in all loiasis-endemic countries</li> <li>• Metrics for annual reporting on morbidity management programmes developed by WHO and disseminated</li> </ul>
2014	<ul style="list-style-type: none"> <li>• 20% of endemic countries verified free of LF transmission</li> <li>• All GPELF countries collect and report data on morbidity management to WHO</li> </ul>
2015	<ul style="list-style-type: none"> <li>• Full geographic coverage with MDA and/or other interventions in all LF-endemic urban areas</li> <li>• Full geographic coverage with MDA and/or other interventions in all countries not endemic for loiasis</li> <li>• Morbidity management plans and policies part of all national LF elimination programmes</li> <li>• Mid-plan assessment of progress, global impact, and remaining challenges</li> </ul>
2016	<ul style="list-style-type: none"> <li>• Full geographic coverage with MDA and/or other interventions to interrupt transmission in heaviest burden countries</li> <li>• Full geographic coverage with MDA and/or other interventions in all countries with co-endemic loiasis</li> <li>• 70% of endemic countries will have met the criteria for stopping MDA and entered post-intervention surveillance</li> </ul>
2020	<ul style="list-style-type: none"> <li>• All countries either verified as free of LF (70%) or under post-MDA surveillance (30%)</li> <li>• Full geographic coverage and access to basic care for lymphoedema (and hydrocele in areas of bancroftian filariasis) in all countries</li> </ul>